513 related articles for article (PubMed ID: 26745555)
1. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
2. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
3. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
[TBL] [Abstract][Full Text] [Related]
4. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
6. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
7. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
[TBL] [Abstract][Full Text] [Related]
8. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
9. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
10. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
11. PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Kruk B; Liebe R; Milkiewicz M; Wunsch E; Raszeja-Wyszomirska J; Lammert F; Milkiewicz P; Krawczyk M
PLoS One; 2018; 13(8):e0202942. PubMed ID: 30161167
[TBL] [Abstract][Full Text] [Related]
12. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
[TBL] [Abstract][Full Text] [Related]
13. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
[TBL] [Abstract][Full Text] [Related]
14. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
[TBL] [Abstract][Full Text] [Related]
15. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
Lee KJ; Moon JS; Kim NY; Ko JS
Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
[TBL] [Abstract][Full Text] [Related]
16. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
17. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
[TBL] [Abstract][Full Text] [Related]
18. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
19. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
20. Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.
Krawczyk M; Bantel H; Rau M; Schattenberg JM; Grünhage F; Pathil A; Demir M; Kluwe J; Boettler T; Weber SN; Geier A; Lammert F;
J Hum Genet; 2018 May; 63(5):621-626. PubMed ID: 29483677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
